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HCV leads to chronic hepatitis C. The morbidity and mortality associated with chronic hepatitis C are mainly attributable to its progression toward cirrhosis and hepatocellular carcinoma. 4 Standard therapy with pegylated interferon (IFN)-␣ and ribavirin fails to clear HCV in ϳ50% of chronically infected individuals. [5] [6] [7] [8] Host factors influence both the natural course of hepatitis C and response to therapy. 9 -12 In 2 cohorts of pregnant women infected under similar conditions with anti-D immunoglobulin preparations contaminated with a single strain of HCV, half spontaneously cleared the infection and half progressed to chronic hepatitis C. 13, 14 Among chronically infected patients, response to treatment differs, even among cases with similar HCV RNA levels and identical viral genotypes. 4 -7 The response rates are associated with viral genotypes, ethnicity, and sex. [15] [16] [17] [18] Previous candidate gene studies reported the role of genetic polymorphisms of HLA, 9, 12, 19 killer immunoglobulin-like receptors, 20 chemokines, and interleukins as well as IFN-stimulated genes [21] [22] [23] [24] [25] on spontaneous HCV clearance. A recent candidate gene study showed that genetic variation in the IL28B gene, which encodes IFN-, is associated with spontaneous HCV clearance, 26 and 3 genome-wide association studies reported associations of SNPs in IL28B with response to antiviral therapy [27] [28] [29] in individuals infected with HCV genotype 1.
In this study, we systematically searched for common human genetic determinants of progression to chronic hepatitis C and of treatment failure using a genome-wide association study in 1362 HCV-infected individuals.
Patients and Methods
Patients were included from the Swiss Hepatitis C Cohort Study and the Swiss HIV Cohort Study, 2 multicenter studies performed at 8 major Swiss hospitals and their local affiliated centers, 30, 31 and from the Medical Clinic for Hepatology and Gastroenterology, Medical University Charité Campus, Virchow-Klinikum Berlin, in Berlin, Germany. Written informed consent, including genetic testing, was mandatory for inclusion, and the study was approved by all local ethical committees. Due to the different genetic predictors of hepatitis C outcomes in racially diverse populations, 15, 18 analyses were limited to the white population. Demographic characteristics including age, sex, HCV risk factors, HCV genotypes, alcohol consumption, markers for hepatitis B virus and human immunodeficiency virus (HIV) infection, HCV viral load, liver biopsy data, and HCV treatment were extracted from clinical databases.
Chronic HCV infection was defined as anti-HCV seropositivity (using enzyme-linked immunosorbent assay and confirmed by immunoblot or recombinant immunoblot assay) and detectable HCV RNA by quantitative or qualitative assays; spontaneous HCV clearance was defined as HCV seropositivity and undetectable HCV RNA in patients without previous antiviral treatment. To avoid the fluctuations of HCV RNA levels during the first year of infection (reviewed by Hoofnagle 32 ), we determined HCV RNA levels at least 1 year after the first documented positive HCV serology. Patients who received at least 80% of the recommended dose of pegylated IFN-␣/ribavirin were considered assessable for response to treatment. Sustained viral response was defined as an undetectable HCV RNA in serum more than Ͼ24 weeks after treatment termination; all other patients were considered nonresponders. Severe fibrosis was considered in patients with a METAVIR score ՆF3.
Genotyping of more than 500,000 common human polymorphisms was performed by the Genomics Platform of the National Center of Competence in Research "Frontiers in Genetics" at the University of Geneva in Geneva, Switzerland, by using Illumina Human1M-Duo, HumanHap550, or Human610W-Quad BeadChips (Illumina, San Diego, CA). Genotype calling was performed using the default settings of the BeadStudio software (Illumina). Calls with a genotyping score Ͻ0.2 were excluded from further analysis. Single nucleotide polymorphisms (SNPs) with a call rate Ͻ90% and individuals with a call rate Ͻ95% were excluded. To enable multiple platform analysis, genome-wide imputation was performed using MACH 33 based on measured SNPs with Ͼ90% call rate, minor allele frequency Ͼ1%, and Hardy-Weinberg P value Ͼ10 Ϫ7 . SNPs with low imputation quality (r2-hat Ͻ0.3) were ignored. Whenever the measured genotype was available, it replaced the imputed value. Population stratification and relatedness were assessed using the ancestry principal components as previously described. 34 -36 One of each genetically related/identical individual pair (relatedness Ͼ0.125) was excluded from further analysis.
To take into account the potential influence of HIV coinfection on spontaneous HCV clearance, HCV monoinfected and coinfected individuals were first analyzed separately; subsequently, we performed a genome-wide meta-analysis of the 2 cohorts. A meta-analysis of association signals obtained from each cohort was performed using inverse variance weighting. Association analysis was performed using a logistic regression model with exact maximum likelihood estimation. Covariates influencing the outcome in the univariate analysis (P Ͻ 0.1), along with the first 2 ancestry principal components, were included in the model. We used a mild P value cutoff as an inclusion criterion for covariates to avoid disregarding potentially important factors. To account for the fact that different genotyping platforms were used, we excluded any SNP with an allele frequency (among patients with chronic infection) that was significantly different ( 2 test, P Ͻ 10 Ϫ4 ) between any 2 platforms. Genomic control was applied to the genome-wide P values yielding a of 1.04 (for the mono-infected cohort) or 1.02 (for the coinfected cohort). These values suggested very mild inflation and confirmed that possible population stratification was sufficiently corrected by including the first 2 ancestry principal components in the models. Bonferroni correction was used to adjust for multiple testing; we used 5 ϫ 10 Ϫ8 as significance threshold.
Resequencing of the candidate locus and recombinant mapping 37 were performed for the purpose of mapping the candidate causal variant or genetic region using the primers indicated in Supplementary Table 1 . We used PHASE version 2.1 software (University of Washington, Seattle, WA) for haplotype inference from population genotype data.
Results

Chronic Versus Spontaneously Cleared HCV Infection
The study included 1362 patients with HCV infection, among whom 347 had spontaneously cleared HCV infection and 1015 had progressed to persistent infection; 914 were HCV mono-infected and 448 were coinfected with HIV/HCV (Supplementary Table 2 ). Several SNPs near the IL28 locus on chromosome 19 were associated with chronic HCV infection with genome-wide significance ( Figure 1 ). The top hit rs8099917 (odds ratio [OR], 2.31; 95% confidence interval [CI], 1.74 -3.06; P ϭ 6.07 ϫ 10 Ϫ9 ; Figure 1 ) is located in an ϳ80-kilobase region encoding 3 cytokines (ie, IL28B, IL28A, and IL29) as T (major allele) to G (minor allele) substitution 7554 base pairs upstream the start codon of IL28B (Supplementary Figure 1 ). The signal in the locus carried 7 SNPs with a P value Ͻ10 Ϫ5 (Supplementary Figure 1A) . The recombination profile indicated that the signal encompassed the whole IL28B gene ( Supplementary Figures 1  and 2) . The effect was similar in HCV mono-infected (OR, 2.49; 95% CI, 1.64 -3.79; P ϭ 1.96 ϫ 10 Ϫ5 ) and HCV/HIV coinfected individuals (OR, 2.16; 95% CI, 1.47-3.18; P ϭ 8.24 ϫ 10 Ϫ5 ). No SNP outside the IL28B/A locus reached genome-wide significance (Figure 1 and Supplementary Tables 3 and 4 ).
The frequencies of the rs8099917 TT, GT, and GG genotypes were 0.58, 0.37, and 0.05 among patients with chronic infection versus 0.78, 0.21, and 0.01 among those with spontaneous clearance, respectively (Supplementary Table 5 ). In the analyses by genotype, both homozygous (GG: OR, 6.02; 95% CI, 2.10 -17.21; P ϭ 8.10 ϫ 10 Ϫ4 ) and heterozygous (GT: OR, 2.24; 95% CI, 1.63-3.07; P ϭ 6.63 ϫ 10 Ϫ7 ) patients had a higher risk of chronicity compared with patients carrying the common genotype (TT) (Figure 2) . Thus, the minor G allele increased the risk of chronicity and was defined as the risk allele. The effect of the genotypes was very similar for both the HCV monoinfected and HCV/HIV coinfected individuals ( Figure 2 ). As expected, male sex was associated with higher chronicity rates (OR, 1.67; 95% CI, 1.29 -2.16; P ϭ 9.5 ϫ 10 Ϫ5 ). The association between sex and HCV persistence was not modified relevantly by adjusting for rs8099917 (OR, 1.80; 95% CI, 1.41-2.31; P ϭ 2.77 ϫ 10 Ϫ6 ), and there was no significant interaction between sex and this SNP (P Ͼ .05).
Among those with chronic HCV infection, there was no significant association of rs8099917 with HCV RNA levels (OR, 1.01; 95% CI, 0.81-1.25; P ϭ .94).
Treatment Response
Next, we assessed whether the SNPs associated with chronicity also influenced response to pegylated IFN-␣/ribavirin combination therapy. Among chronically infected patients, 465 were assessable for response to this treatment (all mono-infected). Factors associated with failure to treatment included HCV genotype 1 or 4 (P Ͻ .001), severe fibrosis (P ϭ .06), male sex (P ϭ .05), older age (P Ͻ .01), and higher pretreatment HCV RNA (P ϭ .04). These variables were included as covariates in the logistic regression.
The frequencies of genotypes TT, GT, and GG for the previously discovered rs8099917 were 0.42, 0.51, and 0.07 among patients with treatment failure versus 0.68, 0.29, and 0.03 among those with sustained viral response, respectively (Supplementary Table 5 ). In the analyses by genotypes, GG homozygous and GT heterozygous patients both had a higher risk of treatment failure compared with patients carrying the common genotype (TT) (Figure 3 ). Minor G allele carriers had a higher risk of treatment failure than the other patients (OR, 5.19; 95% CI, 2.90 -9.30; P ϭ 3.11 ϫ 10 Ϫ8 ), and the G allele was therefore defined as the risk allele.
Clinical Impact
Given that rs8099917 was associated with both chronicity and treatment failure, we assessed data as a theoretical continuum, assuming the history of an infected population ( Figure 4 ). Overall, the proportion of individuals carrying the risk allele increased progressively from a low frequency among patients with spontaneous clearance (24%) to an intermediate frequency among chronically infected patients with sustained viral response to treatment (32%) and to a highest frequency among chronically infected individuals who failed to respond to treatment (58%; P ϭ 3.2 ϫ 10 Ϫ10 ).
A second aspect of importance in clinical care is viral genotype. Therefore, we assessed the joint contribution of host and pathogen genetic risk determinants. Patients were stratified in 4 groups, according to the viral genotypes (viral genotype 2 or 3 vs viral genotype 1 or 4) and host polymorphisms (host rs8099917 G risk allele carriers vs noncarriers; Table 1 ). Treatment failure occurred in only 14% of patients with both low-risk parameters compared with 72% among those with both high-risk parameters (OR, 15.79; 95% CI, 8.37-29.76; P ϭ 1.48E-17; Table  1 ). Among patients infected with genotypes 1 or 4, treatment failure occurred in 72% of risk allele carriers infected compared with only 39% of noncarriers (OR, 4.97; 95% CI, 2.56 -9.66; P ϭ 2.13 ϫ 10 Ϫ6 ). There was no significant association between genetic variation in IL28B and response to therapy among individuals infected with HCV genotype 2 or 3 (OR, 1.58; 95% CI, 0.77-3.25; P ϭ .18). 
Recombinant Mapping
To map the candidate causal variant or genetic region tagged by rs8099917, we resequenced the IL28B locus. To maximize the likelihood of identifying the causal region, we performed recombinant mapping on DNA from individuals selected for having "concordant" or "discordant" genotype-phenotype constellations. Concordant referred to individuals homozygous for the common allele TT with clearance (n ϭ 15) or homozygous for the rs8099917 GG risk allele with chronic infection (n ϭ 15). Discordant referred to individuals homozygous for the common allele TT with chronic infection (n ϭ 15) or the rare individuals (n ϭ 2) homozygous for the GG risk allele with HCV clearance.
Resequencing of the IL28B locus based on recombinant mapping identified 21 SNPs. Haplotype inference led to the identification of 2 main haplotype families ( Figure 5 ). The first family carried the individuals with an HCV clearance phenotype. The second family of haplotypes carried most of the risk of chronicity. The sequence of the IL28B promoter and coding region in discordant individuals that progressed to chronic infection despite absence a Adjusted for fibrosis stage, sex, age, baseline HCV viral load, and the first 2 ancestry principal components. Figure 5 . Resequencing, haplotype inference, and recombinant mapping of the candidate causal region in IL28B. Resequencing for the purpose of mapping the causal variant or region in IL28B was performed by using the primers indicated in Supplementary Table 5 to amplify 4279 base pairs. Sequencing was performed on DNA from 47 individuals representing the various constellations of marker genotype at rs8099917 and the HCV clearance phenotype. This led to the identification of 21 SNPs (#1 to #21, presence of a polymorphism is indicated by a shaded box). Inference of the various haplotypes by using PHASE led to the proposal of a dendrogram with 2 main haplotypic families. The frequent haplotype 1 and derived haplotypes constitute the type I haplotype family, which is generally associated with HCV clearance. The frequent haplotype 10 and derived haplotypes constitute the type II haplotype family, which is generally associated with chronicity. Type II haplotypes are characterized by a defined structure that includes 2 promoter SNPs, a nonsynonymous K70R, and two 3= untranslated region SNPs (marked red). The numbers in the right panel indicate the number of chromosomes with the respective haplotype -rs8099917 combinations by clinical outcome.
of the risk allele of rs8099917 was characteristic of that of individuals with the risk marker. Several specific SNPs were identified as candidates for being causal ( Figure 5 ).
Discussion
This is the first genome-wide association study to report the influence of human genetic variation on the natural control of HCV infection. We found a similar effect of the same genetic marker (rs8099917, located near the IL28B gene) for both natural and treatment-induced control of HCV infection. The lowest carriage frequency of the risk allele (24%) was observed among persons with spontaneous clearance and increased to 32% among chronically infected patients who responded to treatment and to 58% among chronically infected patients who failed to respond. This observation is in line with recent studies that observed a strong association of genetic variation in IL28B with response to therapy [27] [28] [29] and with spontaneous HCV clearance. 26 Our findings strongly point to a major role of the innate immunity in the control of HCV. The mapped region (19q13) encodes 3 cytokine genes (IL28A, IL28B, and IL29) that belong to the IFN-(also named type III IFN) family. IFN-s interact with a transmembrane receptor to induce potent antiviral responses. 38 -40 This antiviral activity is mediated through the activation of the JAK-STAT (IFN-␣s, IFN-␥s, and IFN-s) and MAPK (IFN-␣s and IFN-s) pathways (reviewed by Li et al 39 ) . In vitro and in vivo models have shown the importance of IFN-s in the immune response to several viral pathogens, including herpes simplex virus, 41, 42 cytomegalovirus, 43 HIV, 44 and hepatitis B virus. 45 IFN-1 and IFN-2 blocked HCV replication in human hepatocytic cell lines. 46 -48 IFN-has been proposed, and already tested, as a treatment of hepatitis C. 49, 50 In a phase 1B trial of patients with chronic hepatitis C who are responders/ relapsers, the drug had a robust activity against HCV and limited toxicity. 49, 51 This low toxicity may be explained by a reduced tissue expression of the IFN-receptor compared with that of the IFN-␣ receptor. 49, 50 Thus, IFN-is a promising molecule for the future treatment of hepatitis C, and a dose-ranging phase 2 trial is currently planned.
The genetic data from this study point to IL28B as a critical effector in the control of HCV. The mechanisms linking rs8099917 with differential antiviral responses in HCV-infected patients need to be elucidated. The SNP is located 8 kilobases upstream of the start codon of IL28B. As part of a haplotype block that covers the full length of IL28B, it may interfere with transcription factors and influence gene expression or splicing. In 2 studies, 28, 29 the presence of the rs8099917 risk allele was associated with lower expression of IFN-.
Carriage of the rs8099917 SNP was the strongest genetic predictor of both natural and treatment-induced control of HCV. This SNP was also the strongest predic-tor for response to HCV therapy in white 27, 28 and Japanese 29 populations. Thomas et al reported a strong association of the rs12979860 SNP with spontaneous HCV clearance. 26 rs12979860 is not measured on the Illumina 550 chip and was not available in 149 individuals from our cohort who were genotyped with this chip. In the 1213 individuals with available data, carriage of rs12979860 was highly associated with chronic HCV infection (OR, 1.95; 95% CI, 1.54 -2.48; P ϭ 3.38 ϫ 10 Ϫ8 ) and was in strong linkage disequilibrium with rs8099917 (D= ϭ 0.98; r 2 ϭ 0.5).
SNPs associated with chronic infection may be in linkage disequilibrium with one or several coding SNP(s), or functional noncoding SNP(s), in IL-28B that modulate its function. For this purpose, we used recombinant mapping exploiting the various possible couplings of rs8099917 and the clearance/chronicity phenotype. This led to the identification of 2 main haplotypes (and their derived haplotypes) in the study population. Each haplotypic family had a characteristic promoter and coding region that associates with the clinical phenotype. This constitutes a lead to the causal allele and mechanism of action of IL28B in clearance. Functional studies of gene expression and cytokine production among the different allele carriers will help in addressing this issue.
Our study shows that genetic variation in IL28B is genome-wide the strongest common human genetic determinant for the control of HCV infection. No SNP outside the IL28B/A locus reached genome-wide significance. This further underscores the particular role of innate immune responses for the control of HCV infection. The comparison with genome-wide associations in HIV infection is intriguing, because all significant determinants for the control of HIV were within the major histocompatibility complex on chromosome 6 in genes involved in adaptive immune responses. 52 Our findings could have a substantial impact for prognosis and therapy. For example, individuals with HCV genotype 1 or 4 who carry the risk allele, particularly in homozygosis, will have a very low probability of natural or treatment-induced clearance. These individuals would be prime candidates for novel therapeutic strategies. However, emergence of HCV variants that are resistant to small molecules is almost inevitable if these drugs are not combined with other effective compounds. 53 Individuals with unfavorable host and viral genotypes treated with pegylated IFN-␣/ribavirin and a small molecule would be treated with only one effective drug and therefore at high risk for selection of drug resistance mutations and treatment failure. Future studies need to address the question whether individuals with unfavorable host and viral genotypes would benefit from combining different antiviral molecules to maximize viral response and minimize the risk of drug resistance.
There was no significant association between genetic variation in IL28B and response to therapy among indi-viduals infected with HCV genotype 2 or 3, indicating that the prognostic value of the risk allele for treatment response might be limited to individuals with difficultto-treat HCV genotypes. Another point of clinical importance is the allele frequency of this variant in the population; in a survey of 5435 unrelated Swiss white subjects, 54 the carriage frequency of rs8099917 was 17%. According to the Human Haplotype Map project (Hap-Map; www.hapmap.org), 15% to 19% of white people carry the rs8099917 minor allele. Carriage frequencies differ considerably (range, 2%-31%) in different ethnicities. These differences might therefore contribute to divergent clearance rates observed across populations. 5, 6, 15 Taken together, the increasing evidence for the role of IFN-for both spontaneous and treatment-induced control of HCV infection opens new avenues for prognosis and treatment of HCV infection.
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